Mechanism of action Benztropine is an agent with anti-muscarinic and antihistaminic effects. Its main mechanism of action is presented by the selective inhibition of dopamine transporters but it also presents affinity for histamine and muscarine receptors. 2
This activity examines the indications, mechanism of action, dosing, adverse event profile, and other factors so members of the interprofessional healthcare team can make informed decisions regarding the use of benztropine.
All anticholinergic agents share the same mechanism of action: they block muscarinic receptors in the striatum. Benztropine (Cogentin) has antimuscarinic, antihistaminic, and local anesthetic effects, competing with acetylcholine and other cholinergic mediators at muscarinic receptors in the CNS.
Benztropine primarily acts as an anticholinergic agent, which means it inhibits the action of acetylcholine. Acetylcholine is a neurotransmitter that plays a central role in muscle activation and various other brain functions.
Benztropine works by blocking acetylcholine — a chemical messenger in the brain that controls muscle movement — which helps reduce tremors, stiffness, and involuntary muscle contractions. If that sounds like a lot of science, don't worry.
Benztropine blocks muscarinic receptors, reducing cholinergic activity, and provides antihistaminic sedation that additionally helps decrease movement abnormalities.
Possesses both anticholinergic and antihistaminic effects. In vitro anticholinergic activity approximates that of atropine; in vivo it is only about half as active as atropine. Animal data suggest its antihistaminic activity and duration of action approach that of pyrilamine maleate.
Benztropine acts primarily as an anticholinergic agent by competitively antagonizing muscarinic acetylcholine receptors, with additional antihistaminic effects, though only the anticholinergic properties are therapeutically significant in managing extrapyramidal symptoms. 1.